Maravai Lifesciences Holdings (MRVI) EBT (2020 - 2026)

Maravai Lifesciences Holdings' EBT history runs 7 years deep, the most recent figure standing at -$6.5 million for Q1 2026.

• In Q1 2026, EBT rose 87.61% year-over-year to -$6.5 million; the TTM figure through Mar 2026 stood at -$188.8 million (up 35.29% YoY), while the FY2025 annual figure was -$235.0 million, up 10.14% from the prior year.
• EBT was -$6.5 million for Q1 2026 at Maravai Lifesciences Holdings, up from -$63.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $656.2 million in Q4 2023 to a low of -$172.1 million in Q3 2024.
• Historically, EBT has averaged $39.2 million across 5 years, with a median of -$20.6 million in 2023.
• The sharpest annual moves came in 2023 and 2024: EBT surged 584.41% in 2023, then plunged 737.15% in 2024.
• A 5-year view of EBT shows it stood at $95.9 million in 2022, then soared by 584.41% to $656.2 million in 2023, then tumbled by 107.02% to -$46.1 million in 2024, then tumbled by 36.76% to -$63.0 million in 2025, then soared by 89.64% to -$6.5 million in 2026.
• The last three EBT figures came in at -$6.5 million (Q1 2026), -$63.0 million (Q4 2025), and -$45.1 million (Q3 2025), per Business Quant data.